Literature DB >> 17044027

Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer.

Caroline Rimkus1, Jan Friederichs, Robert Rosenberg, Bernhard Holzmann, Jörg-Rüdiger Siewert, Klaus-Peter Janssen.   

Abstract

Aneuploidy and genetic instability are a hallmark of colorectal cancer and other solid tumors, and they are thought to enhance tumor progression. The gene MAD2L2 (mitotic arrest deficient 2-like 2) encodes the spindle checkpoint protein MAD2L2 (or MAD2B), a key component of a surveillance system that delays anaphase until all chromosomes are correctly oriented. Defects in this mitotic checkpoint are known to contribute to genetic instability, i.e., numerical and structural aberrations of chromosomes. We have previously identified MAD2L2 as significantly upregulated in locally restricted colorectal tumors by gene expression profiling. So far, MAD2L2 has not been reported to play a major role in human cancer in contrast to its homologue MAD2. To address this question, 118 histologically confirmed colorectal lesions were analyzed by quantitative real-time PCR for expression of MAD2L2, and compared to normal colon tissue from 11 patients. Twenty-five out of 118 tumor samples (21%) showed MAD2L2 overexpression of 3-fold or more compared to normal colon, and the fraction of overexpressing tumors increased with tumor stage. Correspondingly, protein levels of MAD2L2 were found to be significantly upregulated in tumors as compared to matched normal tissue. Tumors with upregulated MAD2L2 expression had significantly higher numbers of aberrant mitotic figures (anaphase bridges), an indication of chromosomal instability. Elevated expression of MAD2L2 was significantly correlated with reduced patient survival. By multivariate analysis, MAD2L2 expression was retained as an independent prognostic parameter for patient survival. Thus, our results demonstrate that overexpression of MAD2L2 correlates with bad prognosis in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17044027     DOI: 10.1002/ijc.22155

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy.

Authors:  A Ogden; P C G Rida; R Aneja
Journal:  Cell Death Differ       Date:  2012-06-01       Impact factor: 15.828

Review 2.  Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance.

Authors:  Lauren S Waters; Brenda K Minesinger; Mary Ellen Wiltrout; Sanjay D'Souza; Rachel V Woodruff; Graham C Walker
Journal:  Microbiol Mol Biol Rev       Date:  2009-03       Impact factor: 11.056

Review 3.  Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis.

Authors:  Jinfang Zhang; Lixin Wan; Xiangpeng Dai; Yi Sun; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-02-22

4.  Somatic Mutations in Catalytic Core of POLK Reported in Prostate Cancer Alter Translesion DNA Synthesis.

Authors:  Santosh Yadav; Sudurkia Mukhopadhyay; Muralidharan Anbalagan; Nick Makridakis
Journal:  Hum Mutat       Date:  2015-06-25       Impact factor: 4.878

Review 5.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

6.  MAD2B promotes tubular epithelial-to-mesenchymal transition and renal tubulointerstitial fibrosis via Skp2.

Authors:  Hui Tang; Di Fan; Chun-Tao Lei; Chen Ye; Pan Gao; Shan Chen; Xian-Fang Meng; Hua Su; Chun Zhang
Journal:  J Mol Med (Berl)       Date:  2016-08-03       Impact factor: 4.599

7.  A missense mutation in Rev7 disrupts formation of Polζ, impairing mouse development and repair of genotoxic agent-induced DNA lesions.

Authors:  Maryam Khalaj; Abdolrahim Abbasi; Hiroshi Yamanishi; Kouyou Akiyama; Shuso Wakitani; Sotaro Kikuchi; Michiko Hirose; Misako Yuzuriha; Masaki Magari; Heba A Degheidy; Kuniya Abe; Atsuo Ogura; Hiroshi Hashimoto; Tetsuo Kunieda
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

Review 8.  Development and progression of colorectal neoplasia.

Authors:  Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

9.  MAD2B, a novel TCF4-binding protein, modulates TCF4-mediated epithelial-mesenchymal transdifferentiation.

Authors:  Chun-Fu Hong; Yu-Ting Chou; Young-Sun Lin; Cheng-Wen Wu
Journal:  J Biol Chem       Date:  2009-05-14       Impact factor: 5.157

10.  REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.

Authors:  Huibo Wang; Shu-Yu Zhang; Shuai Wang; Juan Lu; Wenting Wu; Lin Weng; Dan Chen; Yu Zhang; Zhipeng Lu; Jingmin Yang; Yuanyuan Chen; Xu Zhang; Xiaofeng Chen; Caihua Xi; Daru Lu; Shiguang Zhao
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.